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Abstract
Background:  IFN-γ Release Assays (IGRAs) have been licensed for the diagnosis of latent
Mycobacterium tuberculosis infection (LTBI). Their performance may depend on assay format and
may vary across populations and settings. We compared the diagnostic performance of an in-house
T -cell and commercial whole blood-based IGRAs for the diagnosis of LTBI and TB disease in The
Gambia.
Methods: Newly diagnosed sputum smear positive cases and their household contacts were
recruited. Cases and contacts were bled for IGRA and contacts had a Mantoux skin test. We
assessed agreement and discordance between the tests and categorized a contact's level of M.
tuberculosis exposure according to where s/he slept relative to a case: the same room, same house
or a different house. We assessed the relationship between exposure and test results by multiple
logistic regression.
Results: In 80 newly diagnosed TB cases, the sensitivity of ELISPOT was 78.7% and for QFT-GIT
was 64.0% (p = 0.047). Of 194 household contacts 57.1% and 58.8% were positive for ELISPOT and
QFT-GIT respectively. The overall agreement between both IGRAs for LTBI in contacts was 71.4%
and there was no significant discordance (p = 0.29). There was significant discordance between the
IGRAs and TST. Neither IGRA nor TST had evidence of false positive results because of Bacille
Calmette Guérin (BCG) vaccination. However, agreement between QFT-GIT and TST as well as
discordance between both IGRAs and TST were associated with BCG vaccination. Both IGRAs
responded to the M. tuberculosis exposure gradient and were positively associated with increasing
TST induration (p = 0.003 for ELISPOT and p = 0.001 for QFT-GIT).
Conclusion: The ELISPOT test is more sensitive than the QFT-GIT for diagnosing TB disease. The
two tests perform similarly in the diagnosis of LTBI in TB contacts. Significant discordance between
the two IGRAs and between each and the TST remain largely unexplained.
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Background
An estimated one third of the world's population is
infected with Mycobacterium tuberculosis [1]. Interventions
against latent M. tuberculosis infection (LTBI) may have a
key role in controlling the epidemic [2]. Until recently, the
identification of persons with LTBI was only possible
using the tuberculin skin test (TST). However, the TST is
subject to confounding by prior Bacille Calmette Guérin
(BCG) vaccination in certain settings, boosting, reader
variability, and false negative results in immunosup-
pressed persons in particular [3-5].
T-cell interferon gamma (IFN-γ) release assays (IGRAs) are
now licensed for the diagnosis of LTBI [6-8]. They meas-
ure IFN-γ production by sensitized T-cells in response to
stimulation by relatively specific M. tuberculosis antigens.
IGRAs differ from each other mainly with respect to the
technique of IFN-γ detection (enzyme linked immunos-
pot; ELISPOT vs. enzyme linked immunosorbent assay;
ELISA) and the samples utilized (peripheral blood mono-
nuclear cells vs. whole blood). QuantiFERON-TB Gold in-
tube (QFT-GIT, Cellestis Limited, Carnegie, Australia) has
some advantages over ELISPOT: samples can be stored
and run in batches, require less investment in equipment,
and the assay is technically easier to perform. QFT-GIT
uses overlapping peptides of ESAT-6, CFP-10, and TB 7.7
(from Rv2654) antigens. Antigenic stimulation occurs
within the tube used to collect the blood sample.
The performance of IGRAs may vary across populations,
in relation to background disease prevalence, prevalence
of HIV infection, malnutrition, BCG vaccination, expo-
sure to non-tuberculous mycobacteria and other factors
[6-8]. In this study we compared the diagnostic perform-
ance of an ex vivo ELISPOT and the QFT-GIT for the diag-
nosis of LTBI and disease in a TB-endemic tropical setting.
Methods
Participants
As part of an ongoing case contact study, index cases ≥15
years old with pulmonary tuberculosis (PTB) were
recruited between September 2004 and February 2006,
from the major government health centre of the Greater
Banjul area and the Medical Research Council Laborato-
ries outpatients' clinic. Included cases had two sputum
samples positive for acid-fast bacilli by Ziehl-Neelson
stain and M. tuberculosis on culture. After appropriate
counselling, they had blood sampled for HIV test and for
IGRAs.
Household contacts were visited, invited to give informed
consent and interviewed. They were included if they were
≥15 years of age (the age restriction of the overarching
study) and lived the majority of the time on the same
compound as a case. They were not eligible if treated for
TB in the past year and were excluded if diagnosed with TB
within 1 month of recruitment. Contacts underwent a
PPD skin test (2 TU, PPD RT23, Statens Serum Institut,
Copenhagen, Denmark) using the Mantoux technique
and induration was recorded at 48–72 hours. Those with
a positive skin test (mean induration diameter ≥10 mm)
were offered a chest X-ray and those with symptoms
underwent a clinical assessment. Those with TB disease
were referred to the National TB Control Programme for
free treatment. There is no current practice of preventive
treatment in The Gambia.
Four weeks after having a Mantoux test, household con-
tacts that were selected for this comparison had samples
taken for ELISPOT assay, QuantiFERON-TB Gold In-Tube
(QFT-GIT) assay and HIV test. The overarching case con-
tact study has, as per protocol, blood sampling 1 month
after skin test. Contacts were selected for IGRA testing
using an even consecutive balanced sampling frame that
allowed for the possibility that more individuals who
were skin test positive might choose to take part than
those who were skin test negative. Fresh samples from all
participants were processed onsite.
The study was approved by the joint Gambia Govern-
ment/MRC Ethics Committee.
Laboratory procedures
Sputum smears were prepared and stained with auramine-
phenol[9] and confirmed by Ziehl-Neelson (Z-N). Decon-
taminated specimens were inoculated into one slope each
of Lowenstein-Jensen medium (L-J) containing glycerol
and sodium pyruvate respectively and one vial of BACTEC
9000 MB media for isolation of M. tuberculosis. All myco-
bacterial cultures were identified and confirmed using
standard procedures as described previously [10].
The ex-vivo ELISPOT assays for IFN-γ were performed as
previously described [11]. For this study, synthetic,
sequential peptides spanning the length of ESAT-6 and
CFP-10 (ABC, Imperial College, London, UK) were used.
Each peptide was 15 amino acids long and overlapped its
adjacent peptide by 10 residues. ESAT-6 and CFP-10 pep-
tide pools were used at 5 µg/ml. The positive control was
Phytohaemaglutinin (PHA 5 µg/ml; Sigma-Aldrich, UK).
All antigens were tested in duplicate wells. Assays were
counted with an automated ELISPOT reader (AID-GmbH,
Strasberg, Germany). The spot forming unit (SFU) num-
bers counted in each well were automatically entered into
a database. Supplementary details were added by double
data entry. Positive test wells were pre-defined as contain-
ing at least 8 SFUs/well/2 × 105 PBMCs more than nega-
tive control wells [12]. For a positive ESAT-6/CFP-10
result it was necessary for one or more pools of overlap-
ping peptides to be positive. PHA wells were set to at leastBMC Infectious Diseases 2007, 7:122 http://www.biomedcentral.com/1471-2334/7/122
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150 SFUs/well/2 × 105 PBMCs above negative control
wells. Negative control wells were required to have less
than 20 SFUs/well/2 × 105 PBMCs [12]. The ELISPOT was
considered to have failed if the specifications for the neg-
ative control and PHA wells were not met.
The QuantiFERON®-TB Gold In-Tube (QFT-GIT) assay
was carried out according to the manufacturer's instruc-
tions[13] In the first step of this test, 1 ml of whole blood
was collected directly into 2 × 1 ml blood collection tubes
containing either TB-specific antigens (ESAT-6, CFP-10,
and TB7.7) or nil (negative control). They were incubated
at 37°C for 16 to 24 h before plasma was harvested and
stored at -20°C until determination of IFN-γ levels by
QFT-GIT ELISA using a recombinant human IFN-γ stand-
ard. The IFN-γ levels were measured in international units
(IU) with a Dynex ImmunoAssay System ELISA reader
version 6.0 (Dynex Technologies, West Sussex, UK). The
raw data were entered into QFT-GIT analysis software. A
positive result was defined as IFN-g concentration in anti-
gen stimulated tube minus that in the negative control
tube ≥0.35 IU/mL. There was no positive control tube.
Testing for HIV-1 or HIV-2 infection was by competitive
enzyme linked immunosorbent assays (Wellcome Labo-
ratories, Kent, UK) and Western blot (Diagnostics Pasteur,
Marnes-la-Coquette, France).
Ascertainment of exposure
TB contacts were categorized according to where they
slept: in the same bedroom as the index case, a different
bedroom in the same house, or in a different house in the
same compound [14,15].
Data management and analysis
All data were entered using double data entry into an
ACCESS database and checked for errors. The concord-
ance between the ELISPOT, QFT-GIT and TST was assessed
by calculation of a kappa statistic and discordance by
McNemar's test. A random effects logistic regression
model, taking into account household clustering, was
used to assess the relationship between sleeping proximity
to an index case and test results. Age and sex were
included in the analysis at the outset. Other variables
assessed for inclusion in the model were ethnicity, BCG
scar status, smear grade and duration of cough of the
respective index case. The likelihood ratio test was used to
test for trend and for interaction between variables. All
statistical analyses were conducted using Stata software
(version 9; Stata Corp, College Station, TX).
Results
Three hundred and twenty individuals were recruited for
the overarching study, 194 household contacts and 80 TB
cases were selected for this comparison study. Just over
60% of the household contacts were female while 60% of
cases were male. Only 10 (3.7%) of those tested overall
were HIV positive (Table 1). One hundred and eighty-
seven (96.4%) had chest X-rays done at recruitment: six
(3.6%) had some radiological abnormalities present. All 6
were asymptomatic. One had been treated for TB in the
past; and 2 were diagnosed with TB disease over the next
few months. The results for the 2 cases were not included
in those for the 80 TB cases that were sampled at recruit-
ment.
All 80 smear positive TB index cases had both ELISPOT
and QFT-GIT tests performed. Figure 1 shows the distribu-
tion of the IGRA results in index cases. None of the QFT-
GIT tests in cases failed; while there were 5 (6.25%) failed
ELISPOT tests (positive control criteria not met). Of the
75 cases that had both ELISPOT and QFT-GIT results, 59
(78.7%; 95% CI: 67.7–87.2%) cases had a positive ELIS-
POT while 48 (64.0%, 95%CI: 51–73%) were positive by
QFT-GIT. This difference in sensitivity was statistically sig-
nificant (p = 0.047). While there was significant discord-
ance (McNemar's test: p = 0.02) between the two tests as
shown in figure 1, the overall agreement in TB cases was
69.3% (concordance, κ = 0.27).
Valid ELISPOT and QFT-GIT results were available for 182
and 187 contacts respectively. The difference in the pro-
portion of failed tests was not significant (p = 0.24). The
7 QFT-GIT results excluded all failed the criteria for nega-
tive controls as well as 5 (42%) of the excluded 12 ELIS-
POT results – the other 7 (58.3%) did not meet the criteria
for the positive control. Overall, 104 (57.1%) of 182 con-
tacts tested positive to the ELISPOT (95% CI, 49.9%–
64.4%) and 110 (58.8%) of 187 were QFT-GIT positive
(95% CI, 51.7%–65.9%). A total of 175 had both ELIS-
POT and QFT-GIT results. Twenty-six (25.5%) QFT-GIT
positive contacts were ELISPOT negative while 24 (24%)
ELISPOT positive contacts were QFT-GIT negative. The
overall agreement between the two tests was 71.4% (κ =
0.41; 95%CI, 0.27–0.56) and there was no significant dis-
cordance (p = 0.29).
Figure 2 shows the distribution of IGRA results by TST in
household contacts. Just under half were skin test positive
(48.6%). Twenty-three (27.3%) TST positive contacts
were ELISPOT negative and 38 (42.2%) ELISPOT positive
contacts were TST negative. The overall agreement
between the ELISPOT test and TST was 65% (κ = 0.31;
95% CI: 0.16–0.44, discordance, p = 0.055). Sixteen
(18.8%) TST positive contacts were QFT-GIT negative and
33 (36.2%) QFT-GIT positive contacts were TST negative.
The overall agreement between QFT-GIT and TST was
71.1% (κ = 0.43; 95% CI, 0.29–0.57) and there was signif-
icant discordance (p = 0.007).BMC Infectious Diseases 2007, 7:122 http://www.biomedcentral.com/1471-2334/7/122
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A BCG scar was clearly visible in 84 (43.3 %) household
contacts. The univariate odds of a positive ELISPOT or
QFT-GIT test in those BCG scar positive compared to
those without scars was1.23 [0.63–2.4; p = 0.54] and 0.92
[0.41–2.1; p = 0.84] respectively, both remaining non-sig-
nificant after adjustment for possible confounding varia-
bles. The agreement between ELISPOT and TST did not
differ significantly according to BCG scar status being
69.6% (κ = 0.38; 95%CI: 0.16–0.60, discordance p = 0.4)
in those contacts with a BCG scar and 62.4% (κ = 0.26;
95% CI: 0.06–0.47, discordance p = 0.03) in those with-
out a BCG scar. In contrast, agreement between QFT-GIT
and TST was significantly different by BCG scar status (p =
0.03), being 76.5%, (κ = 0.52; 95%CI: 0.31–0.73, dis-
cordance p = 0.11) in those with a scar and 68.2% (κ =
0.37; 95%CI: 0.17–0.58, discordance p = 0.02) in those
without a scar.
In contacts, when a positive TST was defined as ≥5 mm, 86
(81.1%; 95%CI: 73.7–88.6%) of 106 TST positives were
also QFT-GIT positive compared to 73 (71.4%; 95%CI:
62.8–80.3%) of 102 for the ELISPOT but this difference in
proportions was not significant (p = 0.10). With a positive
TST defined as ≥10 mm, 73 (81.1%; 95%CI: 73.0–89.2%)
of 90 were QFT-GIT positive and 72 (72.7%; 95%CI:
63.4–82.0%) of 88 had positive ELISPOTs. When a defi-
nition of ≥15 mm was used, 36 (78.3%; 95%CI: 66.3–
90.2%) of 46 had positive QFT-GIT, similar to the ELIS-
POT with 37 (78.7%; 95%CI: 67.0–90.4%) of 47. These
differences in proportions were also not significant (p =
0.18 and p = 0.96 respectively). Figure 3 shows the pro-
portions of contacts positive by ELISPOT and QFT-GIT
across respective TST categories. There was an association
between both ELISPOT and QFT-GIT results and TST cat-
egories (χ2 = 21.6, p < 0.001 and χ2 = 50.6, p < 0.001
respectively). With increasing TST induration there was a
trend towards increase in the proportions of contacts with
positive ELISPOT and QFT-GIT results and this was statis-
tically significant (p = 0.003 and p = 0.0001 respectively).
The odds of test positivity were also not related to sputum
smear grade (OR = 0.8 [0.3–1.4] for ELISPOT; QFT-GIT
OR = 0.5 [0.1–1.6), or duration of cough (OR, 1.0 [0.9–
1.1] for both tests). The univariate odds of a positive result
across the M. tuberculosis exposure categories (represented
as sleeping proximity to a case) are shown in Table 2.
While neither showed as dramatic a change in positivity
across the exposure gradient as the skin test, both IGRA
tests responded significantly to increasing exposure to an
index case as shown in table 2. However, significance was
lost for both tests after adjusting for age, sex and ethnicity.
Discussion
This study now provides a comparison of an ELISPOT test
with QFT-GIT for the diagnosis of M. tuberculosis infection
and disease in a resource poor TB-endemic tropical set-
Table 1: Characteristics of study population
Characteristics Contacts 
Sleeping proximity gradient
Cases ALL
Separate house Separate room Same room
n = 38 n = 115 n = 41 n = 80 n = 274
Age, years
Mean 29.7 30.0 34.3 31.2 31.0
Median (IQR) 26.5(19–36) 25.0(18–36) 32.0(25–44) 30(23–36) 28(20–37)
Sex
Male 18(47.4) 38(33.1) 20(48.8) 51(63.8) 127(46.4)
Female 20(52.6) 77(66.9) 21(51.2) 29(36.2) 147(53.6)
Ethnic group
Madinka 11(28.9) 47(40.9) 17(41.5) 26(32.5) 101(36.9)
Jola 7(18.4) 32(27.8) 7(17.0) 19(23.8) 65(23.7)
Wollof 2(5.3) 10(8.7) 5(12.2) 8(10.0) 25(9.1)
Fula 8(21.1) 7(6.1) 4(9.8) 11(13.7) 30(11.0)
Others 10(26.3) 19(16.5) 8(19.5) 16(20.0) 53(19.3)
Clinical Findings
BCG scar
Absent 20(55.6) 48(43.6) 24(66.7) 34(42.5) 126(46.0)
Present 16(44.4) 59(53.7) 9(25.0) 19(23.8) 103(37.6)
Uncertain 0(0.0) 3(2.7) 3(8.3) 27(33.7) 45(16.4)
HIV results*
Positive 0(0.0) 3(2.6) 0(0.0) 7(8.8) 10(3.7)
Data are no. (%) of persons unless stated otherwise.
BCG, Bacille Calmette-Guérin
*Data are for 178 contacts and 77 cases.BMC Infectious Diseases 2007, 7:122 http://www.biomedcentral.com/1471-2334/7/122
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ting. Our results suggest both IGRAs, the QFT-GIT and our
in house ELISPOT perform similarly in the diagnosis LTBI
in contacts after recent exposure to a known TB case. How-
ever, the ELISPOT is more sensitive in diagnosing active
PTB in cases.
The sensitivity of 78.7% for the ELISPOT is within our pre-
viously published range 72.6–89.8% [16] and 77–97%
reported elsewhere in literature [7]. Estimates of 55–88%
have been obtained from studies of QFT-GIT among indi-
viduals with active TB – our figure of 64.0% is within this
reported range [17-23]. There are other reports of compa-
rable sensitivity for both IGRA test formats in cases
[24,25]. It is possible that the lack of a positive control
tube for QFT-GIT has led to false negative results. The
Distribution of ELISPOT and QFT-GIT results in TB cases Figure 1
Distribution of ELISPOT and QFT-GIT results in TB cases.
75 cases with 
valid ELISPOT 
and QFT-GIT 
results QFT-GIT results 
for 75 TB cases 
ELISPOT Results 
for 75 TB cases
5 failed ELISPOT 
results excluded  
48 (64%) positive 59 (78.7%) positive 
6 (12.5%) 
ELISPOT negative 
but QFT-GIT 
positive 
17 (28.8%) 
ELISPOT positive 
but QFT-GIT 
negative 
42 (71.2%) 
ELISPOT and 
QFT-GIT 
positive 
16 (21.3%) negative
10 (62.5%) 
ELISPOT negative 
and QFT-GIT 
negative 
27 (36%) negative 
17 (63%) QFT 
negative and 
ELISPOT
positive 
6 (12.5%) QFT-
GIT positive and 
ELISPOT
negative 
42 (87.5%) 
QFT-GIT and 
ELISPOT
positive 
10 (37) QFT-
GIT negative 
and ELISPOT 
negative 
80 Smear and 
culture TB clinic 
Distribution of ELISPOT, QFT-GIT and TST results in household contacts Figure 2
Distribution of ELISPOT, QFT-GIT and TST results in household contacts.
90 (51.4%) TST 
negative
194 contacts with 
TST result 
175 contacts 
with valid 
ELISPOT, QFT-
GIT and TST 
results
85 (48.6%) TST 
positive 
7 (3.6%) of 194 QFT-GIT results 
and 12 (6.2%) of 194 ELISPOT 
results excluded for not meeting 
test criteria 
ELISPOT 
16 (18.8%) 
QFT-GIT 
negative 
23 (27.1%) 
ELISPOT
negative 
62 (72.9%) 
ELISPOT
positive 
QFT-GIT 
69 (81.2%) 
QFT-GIT 
Positive
ELISPOT  QFT-GIT 
33 (36.7%) 
QFT-GIT 
positive 
38 (42.2%) 
ELISPOT
positive 
52 (57.8%) 
ELISPOT
negative 
57 (63.3%) 
QFT-GIT 
negative BMC Infectious Diseases 2007, 7:122 http://www.biomedcentral.com/1471-2334/7/122
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manufacturers have since introduced a positive control
tube which we now use in our new QFT studies.
This study has taken advantage of a reproducible gradient
of exposure to M. tuberculosis in The Gambia. Both tests
responded appropriately to a gradient of recent exposure
to M. tuberculosis and there was no significant divergence
in results according to level of exposure. While we do not
find strong evidence for sensitivity difference in case con-
tacts, the tentative consensus from published literature is
that ELISPOT does have better sensitivity with respect to
LTBI [7].
Consistent with other studies, we show considerable dis-
cordance between the TST and the IGRAs and between the
IGRAs themselves. Our results show significant discord-
ance between the IGRAs in cases. Although about a quar-
ter of ELISPOT or QFT-GIT positive contacts were negative
with the other test, the discordance was not statistically
significant. Discordance between IGRAs in cases and con-
tacts has been described in several reports [18,21,26].
Similar to our results, more of the reported discordance is
due to QFT-GIT negative and ELISPOT positive combina-
tions. Some discordance may be related to test formats
and inclusion of an additional antigen in QFT, but unfor-
tunately remains poorly understood. Reported discord-
ance between each IGRA and the TST ranges from 10–
40% and is most often due to negative TST and positive
IGRA results [6,7]. Discordance between IGRAs and TST
has been related to BCG vaccination, [27-29] and to supe-
rior specificity of the IGRAs, at least in certain settings[15].
More recently, different rates of test conversion and rever-
sion over time have been noted [30,31].
The absence of any significant effect of BCG vaccine on
the TST, ELISPOT and QFT-GIT has remained a constant
feature in Gambian studies, [15,32] and has been
reported in other tropical settings, where BCG is given at
birth [33-35]. It is inconsistent with a published system-
atic review and meta analysis which reported increased
likelihood of a positive TST in BCG vaccinated persons
[36]. A weakness of our study, and most others, is reliance
on the presence or absence of a BCG scar because of the
difficulties in obtaining accurate immunization histories
and/or records.
That the TST was not done at the same time as the IGRAs
may also be a considered a weakness of this study, as it
makes any comparison of IGRA with the TST, subject to
mis-classification bias. However, our primary goal was
not to compare the IGRAs with the TST but to evaluate the
IGRAs in relation to each other. The TST is subject to
boosting. Although, there are some reports of possible
boosting, by a previous TST, of the QFT-GIT and not the
ELISPOT, large conclusive studies are lacking [37-39]. The
1-month time-lag for the overarching study was put in
place to minimise any transient boosting effect on T cell
responses. However, it is possible these results could have
been affected by test conversion, reversion and boosting.
The higher test failure rate of the ELISPOT, compared to
the QFT-GIT, in our study is inconsistent with other stud-
ies, where the opposite has been reported [18,21]. We
note that we have more stringent criteria for an acceptable
test result for ELISPOT than the commercial ELISPOT
based test [40]. The spot counting criteria we used are
based on our published study where we used mathemati-
cal tools to identify a cut-off [12]. Furthermore, the lack of
a positive control for QFT-GIT, as mentioned above, may
have been a factor.
A limitation of IGRAs is their relatively high cost and need
for laboratory infrastructure. The greater through-put of
samples for QFT-GIT gives it some advantage in this light.
However, one would need to demonstrate significant fur-
ther advantage over the TST than is seen here, to justify the
investment for developing countries in particular. The
outstanding question to resolve now is whether IGRAs
show improved predictive value for progression to active
disease, once an individual is infected with M. tuberculosis.
This will require large, possibly multi-site, follow-up stud-
ies of TB case contacts and molecular subtyping of case
and secondary case isolates. Such follow-up studies are
underway in The Gambia.
Conclusion
This study has shown that an in-house ELISPOT has
greater sensitivity than the QFT-GIT for diagnosing active
TB disease, and perform similarly with respect to M. tuber-
culosis infection in The Gambia.
Proportion of positive EC ELISPOT and QFT-GIT across  TST categories Figure 3
Proportion of positive EC ELISPOT and QFT-GIT across 
TST categories.
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Table 2: Univariable and multivariable odds ratios determined by logistic regression (household as random effect), for sleeping proximity as a surrogate marker of exposure to 
M. tuberculosis
ESAT-6/CFP-10 ELISPOT (n = 182) Quantiferon (n = 187) TST (n = 194)........
Positive results
No.(%) of contacts
Unadjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
p-value Positive results
No. (%) of contacts
Unadjusted OR 
(95% CI)
Adjusted OR
(95% CI)
p-value Positive results
No.(%) of contacts
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
p-value
Sleep proximity
Different house 17
(48.6)
11 1 8
(50.0)
1 1 38 
(34.2)
1 1
Different room 63
(57.8)
1.8
(0.6–5.1)
2.3
(0.7–7.0)
64
(57.7)
1.4
(0.6–3.1)
1.5
(0.6–3.6)
55 
(47.8)
1.8
(0.8–4.1)
2.4
(0.9–6.5)
Same room 24
(63.2)
2.3
(0.6–8.5)
4.2
(1.0–18.0)
0.15** 28
(70.0)
2.6
(0.9–7.6)
3.8
(1.2–12.5)
0.08** 25 
(61.0)
3.2
(1.2–8.9)
4.8
(1.3–17.1)
0.06**
*Positive result defined as a mean induration diameter of ≥10 mm.
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